A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab

OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzukawa, Maho, Ohshima, Nobuharu, Tashimo, Hiroyuki, Asari, Isao, Kobayashi, Nobuyuki, Shoji, Shunsuke, Tohma, Shigeto, Ohta, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/
https://www.ncbi.nlm.nih.gov/pubmed/32713920
http://dx.doi.org/10.2169/internalmedicine.5159-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/
https://www.ncbi.nlm.nih.gov/pubmed/32713920
http://dx.doi.org/10.2169/internalmedicine.5159-20

Ejemplares similares